SGLT2 inhibitors started as diabetes drugs. Outcome trial data showing 25–35% reductions in cardiovascular death and a 14% lifespan extension in male mice has pushed them into longevity discussions. Here's the complete picture.
SGLT2 inhibitors are the newest entry in the longevity drug conversation. Bryan Johnson added Jardiance (empagliflozin) and Brenzavvy (bexagliflozin) to the Immortals Rx platform. Peter Attia has discussed empagliflozin at length. The NIA Interventions Testing Program found that canagliflozin (same class) extended lifespan in male mice by 14% — one of the largest effects seen in the ITP's rigorous multi-site protocol.
This article explains what SGLT2 inhibitors do, what the human outcome trial data shows, and how to think about the risk-benefit calculation for non-diabetic longevity use.
SGLT2 (sodium-glucose cotransporter 2) is a protein in the kidney proximal tubule that reabsorbs ~90% of filtered glucose back into the bloodstream. SGLT2 inhibitors block this reabsorber, causing the kidneys to excrete 50–100g of glucose per day in the urine regardless of diet or insulin levels. The downstream effects:
Glucose and insulin: Fasting glucose falls 15–25 mg/dL; HbA1c falls 0.5–1.0%. Crucially, because the mechanism is insulin-independent, the drugs lower glucose without causing hypoglycemia.
Weight: Caloric loss from glycosuria causes 2–4 kg of weight loss over 6 months. The effect plateaus as the body adapts.
Blood pressure: Consistent 3–5 mmHg reduction in systolic BP, likely via osmotic diuresis and reduced arterial stiffness.
Metabolic ketosis: By reducing glucose and insulin, SGLT2 inhibitors shift metabolism partly toward fat oxidation and mild ketone production (typically 0.3–0.5 mmol/L — substantially below diabetic ketoacidosis levels). This mild ketosis may contribute to the cardiac benefits.
Heart failure: The heart failure benefit is perhaps the most surprising. Empagliflozin reduces heart failure hospitalization by 35% in the EMPEROR-Reduced trial — an effect seen within weeks and independent of glucose lowering. The mechanism is debated but may involve reduced cardiac preload, improved myocardial energy metabolism, and reduced inflammation.
EMPA-REG OUTCOME (empagliflozin, 7020 T2D patients with cardiovascular disease): 14% reduction in MACE, 38% reduction in cardiovascular death, 35% reduction in heart failure hospitalization. Published in NEJM 2015.
CREDENCE (canagliflozin, diabetic kidney disease): 30% reduction in the primary renal composite endpoint; significant reductions in cardiovascular death.
DECLARE-TIMI 58 (dapagliflozin, 17,160 T2D patients): 17% reduction in heart failure hospitalization.
These trials established SGLT2 inhibitors as cardioprotective beyond glucose control. The benefits appear to go beyond what would be expected from glucose lowering alone, suggesting direct cardiac and renal effects.
The National Institute on Aging's Interventions Testing Program (ITP) is the gold standard for longevity drug testing: heterogeneous genetic mice, multi-site replication, pre-registered endpoints. In 2022, the ITP published that canagliflozin extended median lifespan in male mice by 14% — the second largest effect ever seen in the ITP (after rapamycin at ~25%). Female mice showed no effect, suggesting an interaction with sex hormone levels.
The proposed mechanism: glucose excretion plus reduced insulin creates a fasting-like metabolic state even without dietary restriction, activating many of the same longevity pathways (AMPK, reduced mTOR signaling) as caloric restriction.
The big question for longevity use: do the cardiovascular benefits seen in diabetic patients with existing cardiovascular disease translate to metabolically healthy people?
Current evidence: No large RCT has been completed in metabolically healthy individuals for longevity endpoints. The DAPA-HF and EMPEROR trials showed benefits in heart failure patients without diabetes, establishing that the cardiac effects extend beyond diabetic populations. But completely healthy 40-year-olds are a different population.
The mechanism argument for benefit: If SGLT2 inhibitors work by creating a caloric restriction-like metabolic state (glucose excretion, reduced insulin, mild ketosis, AMPK activation), there is plausible reason to think even metabolically healthy individuals might benefit from similar pathway activation.
The risks: Genital mycotic infections (the most common — glucose-rich urine creates a favorable environment for yeast). Urinary tract infections. Rare but serious: Fournier's gangrene (very rare, ~1 per 1 million). Diabetic ketoacidosis in predisposed individuals. Volume depletion, particularly problematic with concurrent RAAS inhibitors or diuretics.
SGLT2 inhibitors require a prescription and carry real risk profiles. For metabolically healthy individuals interested in similar metabolic pathway activation:
Berberine activates AMPK and reduces fasting glucose via mechanisms that partially overlap with SGLT2 inhibitor biology. It's not equivalent — the magnitude of effect is smaller and the cardiac outcome data doesn't exist — but it's accessible and well-tolerated.
Time-restricted eating achieves similar metabolic states (reduced insulin, increased AMPK, mild ketosis after overnight fasting) without any pharmacological intervention.
SGLT2 inhibitors have the most compelling cardiovascular outcome trial data of any drug class that has entered the longevity conversation in the last decade. The ITP mouse lifespan data adds mechanistic credibility. The risk-benefit calculation for non-diabetic healthy individuals is genuinely uncertain — the benefits in that population are plausible but unproven, and the risks are real.
This is a prescription drug decision requiring physician involvement, cardiovascular risk assessment, kidney function testing, and monitoring. Longevity physicians who prescribe SGLT2 inhibitors off-label typically do so for patients with specific risk factors (elevated CAC, borderline metabolic syndrome, heart failure risk) where the cardiovascular benefit is most clearly supported.
For everyone else: the OTC metabolic stack (berberine, time-restricted eating, Zone 2 exercise) activates meaningfully overlapping pathways with a superior safety profile and zero prescription requirements.